Altimmune, Inc.
@AltimmuneInc
Followers
1,440
Following
162
Media
103
Statuses
178
We are a clinical stage biopharmaceutical company developing peptide-based therapeutics for obesity and liver diseases.
Gaithersburg, MD
Joined December 2020
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
Mark Robinson
• 360696 Tweets
Ohtani
• 254406 Tweets
Arsenal
• 220858 Tweets
Barca
• 138340 Tweets
ホームラン
• 136077 Tweets
Monaco
• 133921 Tweets
Ter Stegen
• 131432 Tweets
ドジャース
• 94896 Tweets
Raya
• 87317 Tweets
#GHGala3
• 79673 Tweets
Black Nazi
• 76258 Tweets
大谷さん
• 50362 Tweets
大谷さん
• 50362 Tweets
打点10
• 44604 Tweets
Peñarol
• 30190 Tweets
Flamengo
• 27753 Tweets
メジャー史上初
• 20222 Tweets
対象作品
• 19809 Tweets
Martinelli
• 18360 Tweets
#LINEマンガガチャ
• 18083 Tweets
#隣の芝くんは見せてくれない
• 17973 Tweets
#魔王軍最強の魔術師は人間だった
• 17949 Tweets
双葉社フェア開催
• 17949 Tweets
شتيغن
• 16797 Tweets
オオタニサン
• 14449 Tweets
マーリンズ
• 10625 Tweets
イチロー
• 10056 Tweets
Last Seen Profiles
We presented data from our 48-week, placebo-controlled, Ph2 MOMENTUM trial of
#pemvidutide
for the treatment of
#obesity
at the
#ADASciSessions
, showcasing class leading preservation of lean mass, with 78.1% of weight loss coming from body fat: .
#ADA2024
0
7
51
In 2023 we released 48-week data from MOMENTUM, our Phase 2
#clinicaltrial
of
#pemvidutide
for
#obesity
, received
#FastTrack
designation from
#FDA
for pemvidutide in
#NASH
/MASH and more. Explore our latest highlights and see what's next for Altimmune in 2024.
#GLP1
#Glucagon
4
9
49
#DYK
there are more than 16 million people in the U.S. living with
#NASH
/MASH? Our CEO, Vipin Garg, shares his thoughts on the unmet need faced by
#MASH
patients, and the differentiating properties of
#pemvidutide
.
3
3
49
Our CEO, Dr. Vipin Garg, connected with
@BiotechTVHQ
's
@BradLoncar
at
#JPM24
to explore how investigational
#pemvidutide
's
#GLP1
/
#Glucagon
dual agonism works to treat obesity with the added benefit of reducing liver fat & addressing dyslipidemia: .
SF Healthcare Week:
@AltimmuneInc
CEO Vipin Garg explains the science of weight loss drugs and makes the case for GLP-1/glucagon. $ALT
Full video:
2
4
27
3
5
43
Our executive team is attending
#JPM24
in San Francisco this week. Connect with us for 1x1 meetings to learn about our pipeline of next-generation medicines for
#obesity
,
#NASH
and
#HepatitisB
.
#JPM2024
4
5
40
At the
@NashTagConf
both Vlad Ratziu, M.D., and
@AlkhouriNaim
, M.D., presented data that highlighted potent reductions in
#liverfat
and cT1 w/
#pemvidutide
in subjects with
#MASLD
/
#NAFLD
. Learn more:
#NASHTAG2024
4
4
43
Our CMO, Dr. Scott Harris, will be presenting on the role of glucagon-containing dual and triple agonists in the treatment of
#obesity
and
#MASH
at the Global MASLD Conference hosted by
@lifesciences_GE
tomorrow! More here:
0
3
40
We made public data from our 48-week Ph2 MOMENTUM trial of
#pemvidutide
, our investigational GLP-1/glucagon dual receptor agonist for the treatment of
#obesity
. Highlights include reductions in body weight & serum lipids, w/o cardiovascular complications.
3
9
36
#DYK
that there are more than 108M people in the U.S. living with
#obesity
? Some of the comorbidities of obesity include
#dyslipidemia
,
#MASH
,
#MASLD
&
#hypertension
. Our CEO, Vipin Garg, shares his thoughts on the unmet need faced and differentiating properties of
#pemvidutide
:
5
6
37
#Pemvidutide
, our investigational
#GLP1
/glucagon dual receptor agonist, was recently mentioned in a
@statnews
article on
#obesity
drugs that are also being developed for
#liverdiseases
, such as
#MASH
. Read the full article by
@elaineywchen
here:
5
7
35
Today, we shared positive lean mass preservation data for
#pemvidutide
, our
#GLP1
/
#glucagon
dual receptor agonist in development for
#obesity
and
#MASH
, and reported our Q4 and FY 2023
#financialresults
. Learn more about our recent business highlights: .
7
6
37
Tomorrow our CEO, Dr. Vipin Garg will be speaking at
@IamBiotech
’s CEO & Investor conference to discuss innovation in the
#obesity
space. Learn more:
#BIOCEO
6
7
37
This Saturday, we’ll be presenting data on the anti-inflammatory and anti-fibrotic properties of
#pemvidutide
in subjects with
#MASLD
at the
@NashTagConf
in Park City, Utah. Learn more:
#NASHTAG2024
3
10
33
Our CEO, Dr. Vipin Garg took the stage this week at
@IAmBiotech
's
#BIOCEO
conference to discuss next generation
#obesity
therapeutics and the science behind GLP1s and multi-mechanism approaches such as
#GLP1
/
#Glucagon
. See below for photos from the event.
3
2
30
Next week, we will provide a corporate update and publish our fourth quarter and full year 2023 financial results. Learn more: $ALT
2
2
34
Today, we presented data from our Phase 2, MRI-based body composition sub-study of
#pemvidutide
in
#obesity
at
#EASD2024
. Learn more about the data here: .
@EASDnews
0
3
35
In 2024, our CEO, Dr. Vipin Garg, believes we’ll see more companies develop differentiated therapeutics that address the broader health impacts of
#obesity
. Read more of his insights in the latest installment of
@PharmaScrip
's 2024
#ScripAsks
series:
4
2
32
Next week, we will be conducting 1x1 meetings at the
@MorganStanley
Global Healthcare Conference in New York and the
@WellsFargo
Healthcare Conference in Boston. Connect with us to learn more about how we are developing novel therapeutics for patients with
#obesity
and
#MASH
.
0
0
32
On
#WorldObesityDay
, we join
@WorldObesity
and
@ObesityAction
in highlighting the unmet medical need faced by those living with
#obesity
and reiterate our commitment to pioneering the next generation of medicines for the treatment of obesity and its broader health impact.
#WOD2024
5
4
32
We're opening up novel therapeutic pathways for patients living with
#obesity
&
#MASH
.
#Pemvidutide
, our investigational
#GLP1
/
#glucagon
dual receptor agonist, is designed to reduce body weight and liver fat content to improve quality of life. Learn more:
5
3
31
We published data from our
#clinicaltrial
of pemvidutide, a
#GLP1
/
#glucagon
dual receptor agonist, in
#MASLD
in
@JHepatology
. In the study, treatment with
#pemvidutide
resulted in up to 68.5% relative reduction in
#liverfat
. Learn more about the results: .
0
2
31
Learn more about how
#pemvidutide
, our investigational dual receptor agonist for the treatment of
#obesity
&
#MASH
, is designed to improve health outcomes and quality of life by combining the power of GLP-1 and
#glucagon
into one formulation:
0
5
29
We presented data on
#pemvidutide
, our
#GLP1
/
#Glucagon
dual receptor agonist, at the
#ADASciSessions
, which highlighted substantial reductions in lipids associated with increased
#cardiovascular
disease risk:
#ADA2024
0
3
29
#ICYMI
Our CMO, Dr. M. Scott Harris, sat down for an interview with
@radcliffeCARDIO
to discuss the emerging role of glucagon-containing dual and triple agonists for the treatment of
#obesity
and
#MASH
. Watch the full interview here:
0
3
28
#ICYMI
@annikakimc
of
@CNBC
wrote an insightful piece on the positive lean mass preservation of
#pemvidutide
, our investigational
#GLP1
/
#Glucagon
dual receptor agonist for the treatment of
#obesity
and
#MASH
. Read the full article here:
0
1
28
Next week, we will be presenting updated MRI-based body composition data from our 48-week Phase 2 MOMENTUM trial of
#pemvidutide
for
#obesity
at
#EASD2024
in Madrid. Learn more: .
@EASDnews
0
1
29
Harnessing the dual benefits of
#GLP
-1 and
#glucagon
,
#pemvidutide
has the potential to unlock new health outcomes for
#obesity
&
#MASH
by tackling multiple aspects of
#metabolichealth
. Learn more about our approach in this recent
@EverydayHealth
article:
0
2
27
Mucosal immunologist & respiratory physician at Imperial College London,
@P_openshaw
, spoke with
@BBC
about
#COVID19
vaccines and the need for a nasal vaccine to induce a mucosal immune response. Tune in to minute 2:45:40 to listen to his full interview!
2
3
25
It is with deep sorrow that we announce the unexpected passing of our CFO, Richard Eisenstadt. Rich was a cherished member of our team, and we’ll miss his infectious spirit. We express our heartfelt condolences to his family. Full statement here: .
0
0
27
Next week, we'll be hosting 1x1 meetings at Leerink Partners’ Therapeutic Forum on Immunology & Inflammation and
#MetabolicDiseases
. Connect with us to learn more about our mission to develop impactful therapies for
#obesity
and
#MASH
. Learn more: .
0
2
27
Today, we provided a corporate update and published our second quarter 2024 financial results. Learn more about our recent business highlights, including data supporting
#pemvidutide
’s differentiated profile for the treatment of
#obesity
&
#MASH
: . $ALT
0
3
25
#ICYMI
: Our CEO, Dr. Vipin Garg, connected with
@BiotechTVHQ
's
@bradloncar
at
#JPM2024
to discuss how
#pemvidutide
, our investigational
#GLP1
/
#glucagon
dual receptor agonist, works to treat
#obesity
, address dyslipidemia and more:
SF Healthcare Week:
@AltimmuneInc
CEO Vipin Garg explains the science of weight loss drugs and makes the case for GLP-1/glucagon. $ALT
Full video:
2
4
27
5
2
26
Next week, we will provide a corporate update and publish our second quarter 2024 financial results. Learn more: $ALT
0
3
25
Our CEO, Dr. Vipin Garg, and CMO, Dr. M. Scott Harris will be participating in a
#firesidechat
at the JMP Life Sciences Conference tomorrow. More details here:
#Obesity
#MASH
#NASH
0
2
24
#DYK
About 9 to 15 million adults living in the U.S. have
#MASH
? We’re advancing
#pemvidutide
, our novel, investigational
#GLP1
/
#Glucagon
dual receptor agonist, for the treatment of MASH. Visit our website to learn more:
0
4
26
#Pemvidutide
, our novel, investigational
#GLP1
/
#Glucagon
dual receptor agonist, is designed to decrease liver fat and reduce body weight. Learn more about our ongoing Phase 2 IMPACT
#clinicaltrial
evaluating pemvidutide in patients with
#MASH
: .
0
4
25
Our CEO, Vipin Garg recently sat down with
@Reuters
to discuss data from our 48-week Phase 2 MOMENTUM
#obesity
trial of
#pemvidutide
, our investigational
#GLP1
/glucagon dual receptor agonist. Read the full article and learn what’s next here: .
2
4
23
Our CEO, Dr. Vipin Garg, and CMO, Dr. M. Scott Harris, will be participating in
#firesidechats
at the
@Jefferies
Healthcare Conference and the
@GoldmanSachs
Global Healthcare Conference this month. Learn more:
#JefferiesHealthcare
0
1
24
We’re committed to advancing research and developing therapeutic solutions to combat fatty
#liverdisease
. On
#GlobalFattyLiverDay
, we reiterate our dedication to improving health outcomes for the 115 million worldwide impacted by the disease. Learn more:
0
2
23
Today, we provided a corporate update and published our first quarter 2024 financial results. Learn more about our recent business highlights, including advancing enrollment in our IMPACT trial of
#pemvidutide
in
#MASH
: .
0
2
23
Next week, we will provide a corporate update and publish our first quarter 2024 financial results. Learn more: $ALT
0
0
23
Join us at
#EASL2024
next week. We’ll be presenting new data on the anti-inflammatory and anti-fibrotic properties of
#pemvidutide
in patients with
#MASLD
& data detailing pemvidutide’s impact on lipid signatures in
#MASH
. More:
#EASLCONGRESS
@EASLnews
0
1
23
We'll be presenting data on the effect of
#pemvidutide
, our
#GLP1
/
#Glucagon
dual receptor agonist, on cardioinflammatory lipids and new data from our MOMENTUM Phase 2 study of pemvidutide in
#obesity
at
#ADASciSessions
. More: .
@AmDiabetesAssn
0
4
22
Headed to
#EASL2024
in Milan, Italy this week? Don’t miss our presentations on the latest data for
#pemvidutide
in
#MASH
and data from our 24-week Phase 1b randomized, placebo-controlled study in subjects with
#MASLD
.
More here:
#EASLcongress
@EASLnews
0
1
22
Tomorrow, our CEO, Dr. Vipin Garg, and CMO, Dr. M. Scott Harris, will be discussing the latest advancements in
#obesity
therapeutics in a
#fireside
chat at the
@GoldmanSachs
Global Healthcare Conference.
Learn more:
0
0
21
$ALT has partnered with Summit Biosciences, a world-wide leader in nasal spray pharmaceuticals, to manufacture a metered multidose nasal spray presentation of AdCOVID, our intranasal
#COVID19
vaccine candidate. Full announcement:
2
1
19
#DYK
: MASH & MASLD are two of the most significant comorbidities of
#obesity
in the U.S? On
#WorldLiverDay2024
, we reiterate our commitment to developing medicines that treat obesity and its comorbidities, including
#MASH
/
#MASLD
, to help patients live longer and healthier lives.
7
4
20
We presented new data supporting the disease modifying potential of
#pemvidutide
in
#MASH
at
#EASLCongress
, showcasing the possibility for histological improvements, reduced serum lipids and additive effects on MASH resolution and fibrosis:
@EASLnews
0
1
20
This week, our Vice President of Clinical Operations, Randy Brown, M.S., will share strategic insights on the vendor selection process for small to mid-size biotech companies at the Clinical Trials Nexus Conference in San Diego. Learn more:
@BioPharmaNEXUS
0
0
19
Our CMO, Scott Harris, will be exploring our Phase 2b
#clinicaltrial
evaluating
#pemvidutide
, our
#GLP1
/Glucagon dual agonist, in
#MASH
and discussing the role of
#glucagon
biology in overcoming fibrosis at the
@HansonWade
MASH Drug Development Summit!
0
2
19
We are proud sponsors of
@KnowledgeNash
’s Teeing Off on Liver Disease event at Topgolf this year. Join us on Sunday, February 25 as we support initiatives raising awareness and funds for
#MASH
research. Learn more:
2
1
19
Today, $ALT announced positive interim data from our ongoing Phase 1 trial for ALT-801, our investigational GLP-1/glucagon dual receptor agonist. Full text:
4
3
18
IM vaccines aren’t made to stop nasal transmission. AZN showed ~54% reduction in +ve swabs. A combo of
@Astrazeneca
vaccine with our intranasal vaccine could stop asymptomatic spread from those vaccinated. Don’t go into orbit w/
#Sputnik
yet. We'd be over the moon to collaborate
3
1
15
New data from preclinical study of
#COVID19
vaccine candidate, AdCOVID, shows neutralization of South African variant. $ALT full announcement:
1
5
15
We’re proud sponsors of the Liver Forum 16. Together, let's advance research and foster collaboration for the treatment of MASLD/MASH. Learn more:
#MASLD
#MASH
#LiverForum
1
0
16
We've expanded our manufacturing collaboration with
@LonzaGroup
to commission a dedicated manufacturing suite for potential late-stage clinical and commercial production of AdCOVID, our single-dose intranasal
#COVID19
vaccine candidate $ALT Full release:
0
4
15
According to
@WAAYtv
and
@alexWAAY31
AdCOVID is “a potential game changer in the fight against the pandemic.” Click to watch the interview with our Senior Director of Vaccine Development, Dr. Sarah Browne, and
@UABSOM
’s Dr. Frances Lund
#COVID19
0
3
16
Intranasal vaccines have shown to bolster production of IgA antibodies leading to mucosal immunity.
@EricTopol
and
@danieloran
discuss the benefits of a “quick spritz up the nose” to beat
#COVID19
in this essay:
1
3
16
While current
#COVID19
vaccines may create a response that’s highly protective against systemic disease in the lungs, they are less likely to create strong mucosal immunity. Read more from
@ConversationUS
0
4
15
In an
@NPR
segment highlighting next-generation
#COVID19
vaccines,
@Fran_Lund
(
@UABSOM
) discussed $ALT, noting that with an intranasal vaccine, you get the benefits of two kinds of immunity. Listen here:
1
1
12
We're entering the next wave of innovation for
#obesity
therapies. Learn more about investigational
#pemvidutide
's differentiated profile and new data we presented at
@AmDiabetesAssn
's
#ADASciSessions
in
@BerkeleyJr
's
@NBCNews
article:
0
1
14
Today, Dr. Stephen Harrison, a member of our scientific advisory board, will deliver a poster presentation on our Phase 1b study of
#pemvidutide
in subjects with
#NAFLD
at
@AASLDtweets
’ The Liver Meeting.
#TLM23
2
2
13
We would like to express our sorrow and extend our heartfelt condolences to Dr. Stephen Harrison’s family following his tragic and unexpected passing. His countless contributions will leave a profound and lasting legacy. Full statement here: .
0
0
14
This week, our CBO, Raymond Jordt, MBA, and CTO, Bertrand Georges, Ph.D., will be on-site at the
@BIOConvention
in San Diego. Connect with them to learn about how we are spearheading efforts to improve the treatment paradigm for patients with
#obesity
and
#MASH
.
#BIO2024
0
0
13
With vaccines being the epicenter of the news lately, it’s important to understand the different types. Jon Cohen, Senior Correspondent
@ScienceMagazine
, says T cells are “the conductors of the orchestra.” Check out the full video to learn more!
1
1
12
.
@Reuters
reports:
@LonzaGroup
will commission a dedicated suite at its Houston viral vectors factory for clinical and commercial supply of U.S.-based Altimmune's
#COVID19
vaccine candidate. Full text:
0
1
13
“If AdCOVID proves both safe and highly effective, Altimmune just might emerge as a key player in the global coronavirus vaccine market.” Click here to read the full
@TheMotleyFool
article:
#COVID19
#vaccine
3
2
11
Today, we announced that the
@FDA
has granted
#FastTrackDesignation
to our clinical program evaluating
#pemvidutide
, our novel
#GLP1
/Glucagon agonist, for the treatment of
#NASH
. Learn more: .
1
2
12
Living with
#MASH
? Learn more about our Phase 2 IMPACT
#clinicaltrial
evaluating
#pemvidutide
, our novel, investigational
#GLP1
/glucagon dual receptor agonist in patients with MASH, which is currently enrolling patients:
0
2
12
#COVID19
vaccines will play a vital role in society's return to “normalcy." But as Dr. Robert Dracker, Medical Director at Summerwood Pediatrics, explains, "Children are not little adults, [they] react differently not just to vaccines but any medication.”
4
2
12
#ICYMI
@MiriamETucker
published a piece in
@MedscapeEndo
on interim data from our Phase 2 trial of
#pemvidutide
, our investigational
#GLP1
/glucagon dual receptor agonist for the treatment of
#obesity
, presented at
#EASD2023
: .
1
1
11
A new review published in the International Journal of Pharmaceutics further explores the relationship between intranasal and intramuscular administration for SARS-COV-2 vaccines. Full text:
#COVID19
0
1
9
Today, our CEO, Dr. Vipin Garg, and CMO, Dr. M. Scott Harris, will participate in a
#firesidechat
to discuss the latest breakthroughs in
#obesity
therapeutics at the
@Jefferies
Healthcare Conference in New York. Learn more:
#JefferiesHealthcare
0
1
11
$ALT's Dr. Scot Roberts, talked with
@BusinessInsider
on the potential of AdCOVID, our intranasal
#COVID19
vaccine candidate
A future COVID-19 vaccine could be squirted up the nose. The nasal spray could stop transmission, especially in kids.
0
2
7
1
0
10
Dr. Sarah Browne, our Senior Director of Vaccine Development, recently spoke with
@Verywell
about the benefits a nasal vaccine could provide for the general public, especially children. Click here to read the full article
1
2
11
Next month, we’ll be presenting data on the anti-inflammatory & anti-fibrotic properties of
#pemvidutide
from our Phase 1b study in subjects with
#NAFLD
at
@AASLDtweets
’ The Liver Meeting. Learn more:
#TLM23
1
2
11
Another successful $ALT investor call this morning showcasing our 2020 year-end program highlights with AdCOVID, ALT-801, T-COVID and HepTcell. Thanks to all who tuned in!
0
4
11
$ALT is proud to announce that we have begun enrollment for our Phase 1 trial for AdCOVID, our needle-free, single-dose intranasal
#COVID19
vaccine candidate. Full release:
0
4
11
This
#LiverAwarenessMonth
we're bringing attention to the estimated 80M people in the U.S. living with fatty
#liverdisease
and the 2.4M in the U.S. living with chronic
#hepatitisB
infection. Visit
@liverUSA
to access educational resources and support for
#NAFLD
,
#NASH
and
#HBV
.
1
1
10
$ALT CSO Scot Roberts sat down with
@SmithsonianMag
to discuss why an intranasal
#COVID19
vaccine may be the best way to stop viral transmission while also protecting the body from disease. Click here to read:
0
2
9
Last week we began enrollment for our Phase 1 study of AdCOVID, a single-dose, needle-free, nasal spray
#COVID19
vaccine candidate. Click here for more info:
1
4
9
We’re proud to sponsor the
@PBRCNews
Scientific Symposium taking place this week in Baton Rouge. Connect with us on-site for 1x1 meetings to learn more about
#pemvidutide
, our investigational
#GLP1
/glucagon dual receptor agonist for the treatment of
#obesity
&
#MASH
.
5
1
10
"No needles, freezers or second dose needed." ICYMI:
@VictoriaSanchez
interviewed Dr. Scot Roberts and Dr.
@Fran_Lund
on ALT's
#COVID19
vaccine. Watch the full interview here on
@ABC7News
1
4
10